FDA+ roundup: Agency re­opens AI dis­cus­sion pa­per for com­ments amid two-day work­shop

The FDA is re­open­ing the com­ment pe­ri­od on its dis­cus­sion pa­per on us­ing ar­ti­fi­cial in­tel­li­gence in drug de­vel­op­ment, co­in­cid­ing with a two-day work­shop on the top­ic.

The agency in March pub­lished a dis­cus­sion pa­per on the use of AI in drug de­vel­op­ment, which laid out con­sid­er­a­tions and po­ten­tial ar­eas for pol­i­cy de­vel­op­ment in that area. The orig­i­nal com­ment pe­ri­od end­ed on May 1, but the FDA on Tues­day re­opened it for an­oth­er 60 days to al­low for more com­ments fol­low­ing its two-day work­shop on the top­ic be­ing held Tues­day and Wednes­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER